Remedial Health sells medicine wholesale to the 1 million pharmacies and hospitals in Africa. Today in Africa, healthcare providers rely on open-air medicine markets to stock their pharmacies, resulting in inefficiencies and a high risk of buying counterfeits.
Nanopath Inc. is a molecular diagnostics company enabling high-quality molecular testing in minutes.
Swing is creating the next generation of safe and effective digital therapeutics for people with chronic conditions. Our team of passionate scientists, clinicians, and technologists are partnering with some of the world’s top researchers to develop evidence-based transformative digital treatments. Swing’s solutions empower patients to regain control of their illnesses. Together, we are helping people achieve improved health so that they can lead more joyful, vibrant lives.
Boulder is a digital health platform expanding access to effective treatment for opiate use. We aim to move the behavioral health industry forward by offering dramatically better experiences for patients and their care teams.
Quadrant Health provides real-time analysis of EHR and patient messaging data to predict patient harm before it occurs. Founded by Krishna Gorrepati and Anin Sayana in 2021, the company has developed a disease prediction platform designed to identify patient infections and injuries earlier and more accurately than other physicians.
Unicorn Biotechnologies is developing a next-generation biomanufacturing platform to power the cell-based manufacturing revolution, starting with cultivated meat. By providing a clear path to affordably and rapidly scale cultivated meat, we will improve human and planetary health and drive the transition to animal-free agriculture.
Concerto Biosciences rebuilds microbial communities in, on, and around us to heal our bodies and our planet. Products that rebuild microbial communities do not yet exist because no one can map the vast inter-species interaction networks responsible for community behavior. Concerto’s cofounders therefore invented the first-ever ultra-high-throughput platform to experimentally measure millions of microbial interactions. Concerto maps interaction networks that reveal a new class of products called “ensembles”—combinations of microbes that work in concert to shepherd damaged microbial communities to health. The opportunities are enormous: Concerto will become the premier inventor of ensembles across medicine and agriculture, reinventing humanity’s relationship with microbes.
Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.
Epicore Biosystems develops a proprietary wearable microfluidic platform that is ‘skin-like’ and capable of analyzing small droplets of sweat for proteomics, inflammatory markers, hydration, and health biomarkers to enable personalized management of health, performance ,and nutrition. Epicore's wearable sensing technology is based on over two decades of microfluidics and soft materials research by Prof. John Rogers and Dr. Roozbeh Ghaffari at Northwestern University's Querrey-Simpson Institute for Bioelectronics.
Verge Genomics transforms drug discovery with artificial intelligence. Verge was founded by a unique combination of the field's top machine learning experts and seasoned neuroscience drug developers. Together, they share the vision that exponential advances in computational genomics combined with new insights into neuroscience has created a breakthrough opportunity to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease.
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity.
Cellibre is a cellular agriculture company that turns cells into specialized, sustainable factories for the manufacture of globally significant products at scale.
Olaris is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging our CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, we harness the power of the body’s own communication system to discover and develop our pipeline of myOLARIS™ precision diagnostics. To learn more, visit https://www.myolaris.com/ The company was founded in 2013 and is headquartered in Framingham, Massachusetts.
AdaptX (formerly MDmetrix) is a healthcare data analytics, visualization, and AI company that serves hospitals and surgery centers. By empowering medical leaders and frontline clinicians to access, analyze, and improve clinical and workflow outcomes, AdaptX enables providers to improve care and lower costs, transforming clinical operations. Founded in Seattle in 2016, AdaptX was spun out of Seattle Children's Hospital.
Cyrus Biotechnology builds software tools to accelerate basic research in biotech, pharma, and industrial biotechnology. Cyrus Bench delivers an enterprise version of the Rosetta molecular modeling and design toolkit, with the associated array of bio-molecular computation tools. It was founded in 2014 and headquartered in Seattle, Washington.
SHINE deploys its safe, cost-effective, and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy, and other sectors. SHINE’s proprietary medical isotope production processes create molybdenum-99 and non-carrier-added lutetium-177. These important medicines are used in tens of thousands of daily procedures to diagnose and treat heart disease, late-stage cancer, and other serious illnesses. In the future, SHINE plans to scale its fusion technology to help solve one of the energy’s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth.
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
Strateos operates a robotic cloud laboratory that automates chemistry, biology, and tissue analysis to enhance drug discovery processes. By integrating advanced robotics, control systems, and sophisticated imaging and analytics software, Strateos allows pharmaceutical companies to discover new drug candidates more efficiently. The company emerged from a merger between Transcriptic, known for its pioneering robotic cloud laboratory platform, and 3Scan, which specialized in using automation and machine learning to analyze tissue samples. This combination enables Strateos to provide a comprehensive suite of technologies designed to streamline the drug discovery and early development phases. By transforming life science methodologies into data-driven processes, Strateos aims to create a more efficient and cost-effective approach to scientific research, positioning itself as a valuable partner to biotechnology firms seeking to innovate in the field.
miRecule™ is a biotechnology company developing Antibody RNA Conjugate (ARC) therapies for cancer and muscular dystrophy. Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics designed to help patients live a life free from the debilitating symptoms of their disorders. Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality. miRecule is currently applying the DREAmiR™ platform to develop first-in-class therapies, with lead programs in Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy.
Ascent builds life-saving technology for first responders, delivering real-time location and physiological alerting through the Tactical Assault Kit (TAK) platform. Its software integrates with smartwatches to enhance firefighter safety, accountability, and operational decision-making on the ground. Ascent’s technology is deployed across major U.S. metro departments and is expanding internationally through partnerships with OEMs and distributors. Backed by government contracts and venture funding, Ascent is redefining situational awareness for emergency response.
Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic proportions and novel treatments have not kept pace with the urgent need to treat depression, anxiety, drug addiction and many other devastating diseases. Our purpose is to accelerate treatments and fundamentally improve mental health.
Impact Biosystems develops hardware and software solutions for people in the health and fitness space. They provide hardware-connected recovery platforms that provide users with custom measurements of their bodies and enhance the gamifying and socializing experience.
Mendel offers a corporate expense management platform that streamlines financial processes for businesses. Its solutions include automated expense tracking, corporate cards, and real-time reporting to improve visibility and control over company spending. The platform integrates with accounting systems and provides analytics for better financial decision-making.
Intus Care is a healthcare analytics platform that synthesizes financial, clinical, and administrative data to identify, correlate, and visualize trends in long-term care facilities.
Bend helps businesses and individuals manage their long-term financial health and the rising expense of healthcare. Their system is made to maximize revenue, ensure that tax savings opportunities are never missed, and facilitate HSA administration and use. They offer a method of participation, funding, saving, and payment by utilizing technology like artificial intelligence and machine learning.
Clinical Maestro™ by Strategikon Pharma is the only commercially available software platform for the end- to- end management of “clinical business operations”, which is the pharmaceutical industry vertical for planning, outsourcing and budgeting clinical trials. Biopharmaceutical companies outsource 90% of their clinical development pipeline spending billions of dollars engaging in highly complex outsourced relationships with thousands of global service providers, each using their own processes, systems and reporting structures. These sophisticated relationships require complex outsourcing strategies, demanding clinical financial planning, extensive sourcing due diligence and rigorous performance management. Currently the industry manages these activities in Excel, using labor intensive, inefficient processes, costing billions of dollars in infrastructure costs, regulatory non-compliance fines and delays to market. Clinical Maestro takes a radically different approach to the management of clinical portfolio through a transformative redesign of Excel-driven processes into end-to-end integrated workflows, breaking the communication and data integration siloes between pharma companies and their outsourcing partners. Clinical Maestro™ cases studies with leading pharmaceutical companies and CROs demonstrate savings of >80% vs. manual processes, >95% prediction accuracy for clinical study budgets and high user satisfaction and engagement.
Peachy Patients offers a tool designed to make healthcare affordable and accessible to patients. It enables patients to pay their medical bills in one place, earn cash-back on every dollar spent, and be confident that they are always paying the correct price. The Peachy Patients platform puts patients at the center of the healthcare experience, providing them with the tools and resources they need to access care at a reasonable cost.
pulseData offers a machine learning engine that predicts health, so healthcare companies can deliver care precisely to patients and members that can benefit most. The health system generates a tremendous amount of data - deeply specific data on individuals, and pattern behavior data across massive populations. Equipped with the right adaptive, predictive, and precise data science tools, Healthcare Enterprises and Health Providers can partner with A.I. to eliminate preventable sickness. Care management teams uses pulseData to deliver the right care, to the right person, at the right time.
Scipher Medicine develops a healthcare platform designed to determine which drug will work best for each patient. The company is committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. They are building a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, Scipher Medicine can predict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For its first commercial product, they have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs. Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests are then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
Ellipsis Health is an early-stage start-up developing affective computing for existing patient/care team interactions to create a real-time, behavioral health vital sign for each patient. It provides a simple, cost-effective way for health systems to continually screen their patient population for conditions such as depression and get patients the support they need.
Revolutionizing how healthcare data is shared and valued.
Clinical Maestro™ by Strategikon Pharma is the only commercially available software platform for the end- to- end management of “clinical business operations”, which is the pharmaceutical industry vertical for planning, outsourcing and budgeting clinical trials. Biopharmaceutical companies outsource 90% of their clinical development pipeline spending billions of dollars engaging in highly complex outsourced relationships with thousands of global service providers, each using their own processes, systems and reporting structures. These sophisticated relationships require complex outsourcing strategies, demanding clinical financial planning, extensive sourcing due diligence and rigorous performance management. Currently the industry manages these activities in Excel, using labor intensive, inefficient processes, costing billions of dollars in infrastructure costs, regulatory non-compliance fines and delays to market. Clinical Maestro takes a radically different approach to the management of clinical portfolio through a transformative redesign of Excel-driven processes into end-to-end integrated workflows, breaking the communication and data integration siloes between pharma companies and their outsourcing partners. Clinical Maestro™ cases studies with leading pharmaceutical companies and CROs demonstrate savings of >80% vs. manual processes, >95% prediction accuracy for clinical study budgets and high user satisfaction and engagement.
Centivo is a new type of health plan administrator that allows self-funded employers and clinicians to join forces and deliver high quality, affordable healthcare to their employees. An alternative to traditional insurance carriers or third-party administrators, Centivo offers the technology, network, claims processing, customer support, and population health management to fully administer health benefits for all or a portion of an employee population. The Centivo model emphasizes the partnership between individuals and their primary care team as the proper model to coordinate healthcare needs. Centivo’s clinical partners are dedicated to controlling costs and helping members navigate the healthcare system, aided by personalized patient/doctor matching tools. Members are rewarded for working with their primary care team and choosing high-value care and are supported through a user-friendly app and their concierge. Employers get an ally that diligently roots out waste and is accountable for performance. It was formed in 2017 and headquartered in New York, United States.
Concerto Biosciences rebuilds microbial communities in, on, and around us to heal our bodies and our planet. Products that rebuild microbial communities do not yet exist because no one can map the vast inter-species interaction networks responsible for community behavior. Concerto’s cofounders therefore invented the first-ever ultra-high-throughput platform to experimentally measure millions of microbial interactions. Concerto maps interaction networks that reveal a new class of products called “ensembles”—combinations of microbes that work in concert to shepherd damaged microbial communities to health. The opportunities are enormous: Concerto will become the premier inventor of ensembles across medicine and agriculture, reinventing humanity’s relationship with microbes.
Unlearn.AI is a biotech AI company that develops a digital twin service for clinical trials. Digital twins enhance healthcare by assessing health risks before a disease manifests its symptoms, according to some experts. Unlearn brings together a world-class team of experts across pharma, medtech, machine learning, and business who share a vision of using machine learning and biostatistics to improve clinical trials for the benefit of patients and sponsors. Unlearn invented their TwinRCT solution to enable biopharma partners to run faster, more successful clinical trials. A TwinRCT is a randomized trial that uses machine learning to achieve a higher probability of success with a smaller number of patients. As in a traditional RCT, patients are randomized to a treatment group and a control group, but, unlike a traditional trial, a prognostic digital twin is created for every patient using a machine learning model trained on historical data. The treatment effects for the primary and secondary outcomes can all be estimated from the trial with greater precision after correcting for a prognostic score derived for each patient's digital twin. TwinRCTs provide a scientifically-sound method for using deep learning and historical patient data to improve clinical trials.
Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines. It pioneers in the field of Generative Biology, a revolutionary approach to drug development that allows them to program protein-based modalities for the first time. Generate Biomedicines has proved that its machine-learning platform can generate new biological molecules with therapeutic value, accelerating the drug discovery process.
SHINE deploys its safe, cost-effective, and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy, and other sectors. SHINE’s proprietary medical isotope production processes create molybdenum-99 and non-carrier-added lutetium-177. These important medicines are used in tens of thousands of daily procedures to diagnose and treat heart disease, late-stage cancer, and other serious illnesses. In the future, SHINE plans to scale its fusion technology to help solve one of the energy’s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth.
Brio Systems, Inc. operates a comprehensive COVID-19 testing platform designed to assist employers in maintaining workplace safety through on-site testing. Founded in 2017 and based in Boston, Massachusetts, the company provides access to lab-backed polymerase chain reaction (PCR) and antibody testing, along with logistics support, medical oversight, and digital results communication within three days of test collection. Brio’s platform connects employers with FDA-certified laboratories, offering a turnkey solution that includes laboratory testing, fulfillment of collection kits, test requisitioning, medical supervision, and digital reporting. Serving various industries such as manufacturing and food processing, Brio Systems facilitates up to 50,000 tests daily, enabling businesses to protect their workforce and make informed risk-mitigation decisions.
Unlearn.AI is a biotech AI company that develops a digital twin service for clinical trials. Digital twins enhance healthcare by assessing health risks before a disease manifests its symptoms, according to some experts. Unlearn brings together a world-class team of experts across pharma, medtech, machine learning, and business who share a vision of using machine learning and biostatistics to improve clinical trials for the benefit of patients and sponsors. Unlearn invented their TwinRCT solution to enable biopharma partners to run faster, more successful clinical trials. A TwinRCT is a randomized trial that uses machine learning to achieve a higher probability of success with a smaller number of patients. As in a traditional RCT, patients are randomized to a treatment group and a control group, but, unlike a traditional trial, a prognostic digital twin is created for every patient using a machine learning model trained on historical data. The treatment effects for the primary and secondary outcomes can all be estimated from the trial with greater precision after correcting for a prognostic score derived for each patient's digital twin. TwinRCTs provide a scientifically-sound method for using deep learning and historical patient data to improve clinical trials.
Brio Systems, Inc. operates a comprehensive COVID-19 testing platform designed to assist employers in maintaining workplace safety through on-site testing. Founded in 2017 and based in Boston, Massachusetts, the company provides access to lab-backed polymerase chain reaction (PCR) and antibody testing, along with logistics support, medical oversight, and digital results communication within three days of test collection. Brio’s platform connects employers with FDA-certified laboratories, offering a turnkey solution that includes laboratory testing, fulfillment of collection kits, test requisitioning, medical supervision, and digital reporting. Serving various industries such as manufacturing and food processing, Brio Systems facilitates up to 50,000 tests daily, enabling businesses to protect their workforce and make informed risk-mitigation decisions.
Savvy's healthcare payments platform enables millions of businesses and the brokers they work with to offer consumer-focused healthcare for the first time. Savvy is backed by Y Combinator.
Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas include oncology blood cancers, solid tumors, and genome editing validation.
Emulate is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.
Emulate is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.
Matchwell, a Medical Solutions company, is the tech-enabled job marketplace that empowers healthcare organizations to access and manage a flexible workforce in the most efficient model in the industry. By leveraging AI and providing full transparency and direct access, healthcare organizations can better utilize their existing workforce while attracting new clinicians who are seeking work on their terms. With more than 50,000 on-platform clinicians and 1,000 sites of care under contract, Matchwell is helping redefine the merits and power of a flexible workforce. For more information, visit wematchwell.com.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
NeuroFlow is a platform to be a resource and asset to healthcare providers in their pursuit to get patients better and improve lives. It is a cloud-based platform that empowers healthcare providers to track, assess, and engage patients using evidence-based practices to support their mental health. The suite of tools supports remote monitoring and behavioral health integration across the continuum of care, including psychology, primary care, and pain management settings, to increase patient engagement and improve compliance.
Notable Labs is a personalized testing service for cancer patients that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor without a clinical trial.
miRecule™ is a biotechnology company developing Antibody RNA Conjugate (ARC) therapies for cancer and muscular dystrophy. Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics designed to help patients live a life free from the debilitating symptoms of their disorders. Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality. miRecule is currently applying the DREAmiR™ platform to develop first-in-class therapies, with lead programs in Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy.
Tembo Health is a telemedicine company serving retirement homes, senior care centers and skilled nursing facilities to connect patients with specialty services like psychiatry and cardiology. The platform connects the specialists to patient data and collaborates with the nursing staff to provide better care plans.
Allevi offers bioprinters that enable users to experiment with any biomaterial, work with any cell line, and print in any geometry. Its platform empowers novice and expert 3D bioprinting users alike to quickly and easily achieve their goals.
Olaris is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging our CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, we harness the power of the body’s own communication system to discover and develop our pipeline of myOLARIS™ precision diagnostics. To learn more, visit https://www.myolaris.com/ The company was founded in 2013 and is headquartered in Framingham, Massachusetts.
Vincere Health is a Techstars-backed health tech company founded at the Harvard Innovation Labs in 2019. They use a combination of intelligent, frequent incentives, objectively verified health data, and health coaching to drive behavior change to solve healthcare's biggest challenges - starting with smoking cessation.
Mighty Health connects users to coaches to help them become healthier through exercise, nutrition, and wellness.
E25Bio specializes in the development of rapid diagnostic tests for epidemic fever viruses. It is dedicated to preventing severe downstream health outcomes with the use of mobile, fast, real-time reporting to create unprecedented large datasets to guide informed and timely responses for the control of disease spread. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Parachute Health is a provider of medical equipment ordering software. Their mission is to improve patient care through transparent and seamless coordination of medical equipment and supplies.
Emerald was founded in 2010 by two scientists and life-long friends from Philadelphia with a singular vision of how a biotechnology company should run. Frustrated by the continual deceleration of innovation and the exponentially increasing R&D costs in the pharmaceutical sector, Emerald models itself after the legendary start-up companies of the mid-20th century that built the core technologies underlying the meteoric rise of the semiconductor industry. The team places as much focus on building tools around how scientific research is conducted as they do on their proprietary anti-viral therapies. In this way, Emerald is striving to bring a Moore’s law-like acceleration to life sciences innovation.
StemoniX is a biotechnology company that focuses on stem cell technologies to meet the demands of drug discovery and personalized medicine. StemoniX is revolutionizing the production, growth, and development of stem cell and stem cell technologies. It was founded in 2014 and headquartered in Maple Grove, Minnesota.
NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeper and more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain
Allevi offers bioprinters that enable users to experiment with any biomaterial, work with any cell line, and print in any geometry. Its platform empowers novice and expert 3D bioprinting users alike to quickly and easily achieve their goals.
SleepSpace is the first Sleep Operating System designed to connect all the devices in the smart bedroom of the future. We give every human a deeper night of sleep using the science of sound, vibration, and light. Our technology more accurately measures sleep than any other wearable and connects with most wearables, like Apple Watch, Oura, Biostrap, Eight Mattress, and more. We developed proprietary nearable sleep sensing technology that turns your smart phone into a smart bed. We empower coaches and clinicians to get a clearer picture of their patients and give more effective personalized interventions using our platform. SleepSpace is a tool to both deliver clinical sleep programs and to give clinicians a clear picture of the patient's objective device data and their subjective experience of sleep. We have sold the technology into major mattress brands, hotels, and corporate wellness initiatives and have received more than $3.5 mm in grant awards from the NIH.
PharmaCCX operates a market access platform with a simple and configurable infrastructure for planning, negotiating, and managing deals. The company software increases the capacity of market access teams at pharma and payers to plan, execute and administer innovative payment models
ClearView MD is a predictive analytics firm that is powering the transition to value-based care by providing health systems interventions that lead to higher patient and staff satisfaction, lower costs, and the ability to treat more patients. ClearView MD identifies inefficiencies on client's workflows, and recommends steps to improve your scheduling, staffing, and facility utilization. The company was founded by Rajiv Sivendran and Artur Menzeleev, with headquarters in Boston, Massachusetts.
NeuroFlow is a platform to be a resource and asset to healthcare providers in their pursuit to get patients better and improve lives. It is a cloud-based platform that empowers healthcare providers to track, assess, and engage patients using evidence-based practices to support their mental health. The suite of tools supports remote monitoring and behavioral health integration across the continuum of care, including psychology, primary care, and pain management settings, to increase patient engagement and improve compliance.
Eva develops an accessible and non-invasive wearable device designed to detect breast cancer risks. The company's wearable device is equipped with tactile sensors which are designed to map the surface of the breast and surrounding areas, allowing women to keep a track on the changes in breast temperature, size, and weight, with the help of biosensors inside the cup which constantly monitors information.
Lumiata is transforming the healthcare enterprise through the application of AI. Bringing predictive power within reach of data science teams and business users, we’re driving predictability and precision at scale — empowering providers and payers to reduce risk and manage costs and move out of reliance on flat data into a future of insights. Lumiata machine learning tools and pre-trained models comprise a scalable platform purpose-built for healthcare. Lumiata products are built from more than 120 million patient records, in-depth clinical knowledge, and its proprietary clinical IP. Lumiata enables healthcare organizations to explore use cases such as underwriting and care management. Lumiata is proud to be backed by Khosla Ventures, Blue Venture Fund, Defy.vc, and AllegisNL Capital. Team Lumiata is distributed across Silicon Valley, Dallas, and Guadalajara, Mexico.
At WelbeHealth, we envision a world in which every human being is able to participate fully in life through their final days. We serve frail seniors through a model of comprehensive medical and social care called PACE (Program of All-Inclusive Care for the Elderly), helping our participants live better, longer, and more independently. Founded by a seasoned group of physician entrepreneurs, our leadership team hails from leading payer and provider organizations such as GoHealth Urgent Care, BAYADA Home Health, AirStrip Technologies, Evolent Health, and On Lok. With funding from leading venture capital firms, we're looking for team members who are inspired to help us deliver on our mission of unlocking the full potential of the most vulnerable seniors in our communities. Our colleagues are energized by working in diverse groups toward our shared purpose, are eager to drive groundbreaking innovations, and have the courage to care for our participants with empathy and love.
Bainbridge Health provides hospital systems with a clinical intelligence and data analytics platform to improve medication safety. It provides hospital safety professionals with an infusion pump management software solution to better manage pump data and enhance patient safety. Bainbridge Health also offers a clinician-focused infusion pump management system known as InfusionWare that enables clinicians to manage infusion data in one centralized location.
SHINE deploys its safe, cost-effective, and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy, and other sectors. SHINE’s proprietary medical isotope production processes create molybdenum-99 and non-carrier-added lutetium-177. These important medicines are used in tens of thousands of daily procedures to diagnose and treat heart disease, late-stage cancer, and other serious illnesses. In the future, SHINE plans to scale its fusion technology to help solve one of the energy’s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth.
American Gene Technologies (AGT) is focused on creating long-term value for patients, society, investors and donors by developing and testing cutting-edge gene therapies to cure some of humanity’s worst diseases. AGT’s HIV cure clinical trial could not only lead to a blockbuster drug that brings relief to one of society's most elusive epidemics, but it could prove the efficiency and effectiveness of AGT’s platform technologies to cure dozens of diseases ranging from viruses to cancers.
NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeper and more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain
Manus Bio Inc. recreates plant processes in microorganisms to produce natural ingredients through fermentation. The company’s microbial platform converts sugar sources into ingredients with applications, such as flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. It merges metabolic engineering, protein engineering, and systems biology technologies to generate microbes that produce various plant-based ingredients. The company has a strategic partnership with BBGI Public Company Limited. Manus Bio Inc. was formerly known as Manus Biosynthesis, Inc. and changed its name to Manus Bio Inc. in June 2018. The company was founded in 2011 and is based in Cambridge, Massachusetts. It has manufacturing facilities in Cambridge, Massachusetts; and Augusta, Georgia.
Lumiata is transforming the healthcare enterprise through the application of AI. Bringing predictive power within reach of data science teams and business users, we’re driving predictability and precision at scale — empowering providers and payers to reduce risk and manage costs and move out of reliance on flat data into a future of insights. Lumiata machine learning tools and pre-trained models comprise a scalable platform purpose-built for healthcare. Lumiata products are built from more than 120 million patient records, in-depth clinical knowledge, and its proprietary clinical IP. Lumiata enables healthcare organizations to explore use cases such as underwriting and care management. Lumiata is proud to be backed by Khosla Ventures, Blue Venture Fund, Defy.vc, and AllegisNL Capital. Team Lumiata is distributed across Silicon Valley, Dallas, and Guadalajara, Mexico.
Celularity is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Iris Plans is a tech-enabled service that provides Advance Care Planning (ACP), or “healthcare planning,” to people with serious medical conditions. ACP’s proven benefits result in people receiving higher quality care, less stress on loved ones, higher satisfaction, and lower costs. Iris Plans is the first organization offering nationwide, complete ACP that is tailored specifically to individuals’ circumstances and preferences.
Manus Bio Inc. recreates plant processes in microorganisms to produce natural ingredients through fermentation. The company’s microbial platform converts sugar sources into ingredients with applications, such as flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. It merges metabolic engineering, protein engineering, and systems biology technologies to generate microbes that produce various plant-based ingredients. The company has a strategic partnership with BBGI Public Company Limited. Manus Bio Inc. was formerly known as Manus Biosynthesis, Inc. and changed its name to Manus Bio Inc. in June 2018. The company was founded in 2011 and is based in Cambridge, Massachusetts. It has manufacturing facilities in Cambridge, Massachusetts; and Augusta, Georgia.
Clear Labs offers next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. The company's platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens and support public health initiatives. The company focuses on delivering actionable insights to enhance safety and operational efficiency in various sectors.
Iris Plans is a tech-enabled service that provides Advance Care Planning (ACP), or “healthcare planning,” to people with serious medical conditions. ACP’s proven benefits result in people receiving higher quality care, less stress on loved ones, higher satisfaction, and lower costs. Iris Plans is the first organization offering nationwide, complete ACP that is tailored specifically to individuals’ circumstances and preferences.
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Florence advances clinical research through software. The Florence Platform replaces paper investigator site files, trial master files and source binders with a shared platform.
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.